Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
Abstract: A method for producing a solution including a positron emitting zinc cation of 63Zn, and the method comprises bombarding a solution target including 63Cu with high energy protons to produce a solution including a positron emitting zinc cation. A method for detecting or ruling out Alzheimer's disease in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to ?-amyloid in the patient, and acquiring an image to detect the presence or absence of ?-amyloid in the patient. A method for detecting or ruling out cancer in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to tissue in the patient; and acquiring an image using a medical imaging technique to detect zinc distribution in tissue in the patient.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
August 31, 2021
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Timothy R. Degrado, Mukesh K. Pandey, Hendrik Petrus Engelbrecht, Val J. Lowe
Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
August 24, 2021
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Christian Preihs, Jing Yu, Veronica Clavijo Jordan, Yunkou Wu, Khaled Nasr, A. Dean Sherry, Sara Chirayil
Abstract: Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
August 24, 2021
Assignee:
Washington University
Inventors:
Vijay Sharma, Jothilingam Sivapackiam, Sundaram S. M. Guruswami
Abstract: Disclosed are: an intermediate capable of high-purity synthesis of gadobutrol which can be used as an MRI contrast agent; and a gadobutrol production method using same. The gadobutrol intermediate is represented by Chemical Formula 2 in the specification.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
August 17, 2021
Assignee:
ENZYCHEM LIFESCIENCES CORPORATION
Inventors:
Jae Young Lee, Jong Soo Lee, Byung Kyu Kang, Sang Oh Lee, Byouong Woo Lee, Dae Myoung Yun, Jae Hun Bang, Choi Kyung Seok
Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.
Abstract: The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
Type:
Grant
Filed:
November 20, 2015
Date of Patent:
July 20, 2021
Assignee:
TECHNICAL UNIVERSITY OF DENMARK
Inventors:
Thomas Lars Andresen, Linda Maria Bruun, Trine Bjørnbo Larsen, Rasmus Irming Jølck, Anders Elias Hansen
Abstract: This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include 18F-labeled BODIPY compounds and derivative thereof. Also provided are tracer kits containing a sterile formulation of a BODIPY dye either in a radio-labeled or pre-labeled state, and methods for imaging heart perfusion using the 18F-labeled dual mode tracers.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
July 20, 2021
Inventors:
Peter S. Conti, Zibo Li, Shuanglong Liu, Dan Li
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Grant
Filed:
August 2, 2019
Date of Patent:
July 13, 2021
Assignee:
CHDI Foundation, Inc.
Inventors:
Celia Dominguez, Samuel Coe, Peter David Johnson, Michael Edward Prime, Christopher John Brown, Sébastien René Gabriel Galan, Paul Richard Giles, Jonathan Bard, Elise Luciennen Paulette Gadouleau, Thomas Martin Krülle, Daniel Clark-Frew, John Wityak, Alex Kiselyov, Sarah Hayes
Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
July 13, 2021
Assignee:
ChemoCentryx, Inc.
Inventors:
Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Abstract: A method tor the preparation of a highly polarized nuclear spins containing sample of an organic or inorganic material, containing H or OH groups or adsorbed water molecules. Such highly polarized nuclear spins containing samples can be subjected to nuclear magnetic resonance (NMR) measurement and/or can be thawed and immediately administered to an individual undergoing a magnetic resonance imaging (MRI) scan. The method is based on generating unstable radicals on the surface of the sample in the presence of ionized environment followed by cooling the sample to cryogenic temperatures. A device for carrying out a particular step of said method is also discloses.
Type:
Grant
Filed:
June 3, 2020
Date of Patent:
June 22, 2021
Assignees:
Technion Research & Development Foundation Limited, Yeda Research and Development Co. Ltd.
Abstract: A method for producing an iodine radioisotopes fraction, comprising the steps of dissolving enriched uranium targets forming a slurry, filtering said slurry, absorbing salts of iodine radioisotopes on an aluminium resin doped with silver and recovering said iodine radioisotopes fraction, is disclosed. The recovery of the iodine radioisotopes fraction, in particular of I-131, comprises washing the aluminium resin doped in silver using a solution of NaOH and eluting of iodine radioisotopes by a solution of thiourea, and collecting an eluate containing said iodine radioisotopes in a thiourea solution.
Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Grant
Filed:
October 23, 2017
Date of Patent:
May 4, 2021
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
April 20, 2021
Assignee:
Drexel University
Inventors:
Steven Wrenn, Brett Angel, Andrew Kohut, Aaron Fafarman, Michael Cimorelli
Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
April 20, 2021
Assignees:
The European Atomic Energy Community (EURATOM), Represented by the European Commission, Universität Heidelberg
Inventors:
Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Uwe Haberkorn, Frederik Giesel, Clemens Kratochwil